Answers are grounded in this paper and cite their sources.
Review reveals iPSC models illuminate links between cardiometabolic syndrome and cancer risks, suggesting new therapies.
Heart disease and cancer share common risk factors, genetic predispositions, and metabolic and inflammatory components. Metabolic reprogramming can drive disease progression in both, with cardiometabolic syndrome-marked by obesity, insulin resistance, dyslipidemia, and hypertension-contributing to cancer development. Studies link around 20% of cancer cases to obesity, while elevated glucose and triglyceride levels increase the risk of liver, thyroid, and respiratory cancers. Beyond treatment-related cardiotoxicity, cancer patients often have pre-existing cardiovascular disease (CVD) at diagnosis, highlighting their bidirectional relationship. Patient-specific induced pluripotent stem cells (iPSCs) offer a powerful platform to study these links at a personalized level. iPSC models help explore shared molecular mechanisms, metabolic dysregulation, inflammation, and cardiotoxicity. This review examines emerging themes in cardio-oncology and cardio-metabolism, emphasizing how iPSC-based approaches can reveal disease connections and inform new therapies.
No takes yet. Share an insight, caveat, or question.
Kojic et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: